ArticleOncotarget2017
Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- High-throughput engineering of bispecific antibodies to enhance macrophage-mediated cytotoxicity of B-cell lymphoma.Nature communications · 2026Article
- Targeted Therapy in Hepatobiliary Pancreatic Cancer (HPC): Advantages and Advancements of Antibody Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs.International journal of molecular sciences · 2026Review
- Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?Neuro-oncology · 2025Review
- Unbiased discovery of antibody therapies that stimulate macrophage-mediated destruction of B-cell lymphoma.bioRxiv : the preprint server for biology · 2024Article
- Cancer stem cell-immune cell crosstalk in the tumor microenvironment for liver cancer progression.Frontiers of medicine · 2024Review
- Review
- Comparison of "framework Shuffling" and "CDR Grafting" in humanization of a PD-1 murine antibody.Frontiers in immunology · 2024Article
- Checkpoint CD24 function on tumor and immunotherapy.Frontiers in immunology · 2024Review
- From mechanism to therapy: the journey of CD24 in cancer.Frontiers in immunology · 2024Review
- Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200.International journal of molecular sciences · 2023Review
- CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer.Cancer immunology, immunotherapy : CII · 2023Article
- Current understanding of cancer stem cells: Immune evasion and targeted immunotherapy in gastrointestinal malignancies.Frontiers in oncology · 2023Review
- CD24: A Novel Target for Cancer Immunotherapy.Journal of personalized medicine · 2022Review
- Antibody-drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.Theranostics · 2021Review
- Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective.Molecules (Basel, Switzerland) · 2020Review
- The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors.International journal of molecular sciences · 2020Review
- Sagacity in antibody humanization for therapeutics, diagnostics and research purposes: considerations of antibody elements and their roles.Antibody therapeutics · 2020Review
- Review
- Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer.International journal of molecular sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cluster of differentiation 24 (CD24) is a specific surface marker involved in the tumorigenesis and progression of hepatocellular carcinoma (HCC). However, all reported anti-CD24 antibodies are murine ones with inevitable immunogenicity. To address this, a method using both molecular structure and docking-based complementarity determining region (CDR) grafting was employed for humanization. After xenogeneic CDR grafting into a human antibody, three types of canonical residues (in the VL/VH interface core, in the loop foundation, and interaction with loop residues) that support loop conformation and residues involved in the antigen-binding interface were back-mutated. Four engineered antibodies were produced, among which hG7-BM3 has virtually identical 3-D structure and affinity parameters with the parental chimeric antibody cG7.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.